Site Members can sign up for company wide alerts
Investigation Overview
February 17, 2016 (Update) - On February 8, 2016, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial ofavoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary angioedema (HAE) attacks. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) declined to as low as $...
You must register (for free) or login to view the entire investigation.